Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
A chemical called cysteamine has long been of interest as a potential therapy for Huntington's disease. Now, Raptor Pharmaceuticals has announced the interim results of a study of cysteamine in HD patients. The trial failed to meet its pre-specified goal, but there are some interesting details in the data suggesting the ongoing trial deserves attention.
Studies have shown that HD patients tend to get less efficient sleep, fewer hours of sleep, and wake up more times during the night. However, sleep in Huntington’s is under-researched because historically scientists have investigated HD as a disease of movement impairment, and sleep problems don’t seem to have anything to do with movement impairment.
Our final reports from the Huntington's disease therapeutics conference in Palm Springs.
HDBuzz reports from the second day of science at the Huntington's disease therapeutics conference in Palm Springs.
The Huntington's Disease Therapeutics Conference, held annually, is the biggest meeting of scientists working towards treatments for HD. Here's our report from the opening day of science sessions at the Conference.
The results are in from the Reach2HD study, which was designed to test the experimental drug PBT2 for early and mid-stage Huntington's disease. The drug seems safe and well-tolerated at the doses that were tested, but we have major concerns about the way the results have been reported.
The results of a new study called PRECREST, investigating whether the nutritional supplement creatine can slow Huntington's disease progression, have just been published. Uniquely, this studied the effects of high-dose creatine supplementation in people carrying the HD mutation, but without clear disease symptoms.
Many types of stresses occur within cells that have the HD gene, and examining how simple organisms cope can help scientists define new targets for HD drugs. A new study examines yeast to determine which proteins can protect these cells from damage and death, uncovering a protective antioxidant and a related drug.
Copper, the metal, may play a role in worsening the symptoms of Huntington’s disease. Bing Zhou and his team looked for connections between HD and the amount of copper in neurons. They report that reducing copper in neurons or keeping it from binding to the HD protein improves symptoms.